AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway.

Impact · against what's priced in

The article provides no new material catalysts for ABBV, as the strong performance of its successor drugs and the resulting share price appreciation are already fully reflected in the current valuation. The discussion regarding dividend yield compression is a mathematical result of this already-priced-in price momentum.

ABBV+0.00: Already priced in
The price assumes: SKYRIZI and RINVOQ replacing HUMIRA's lost revenue

AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway.

What matters in this story

Schwab's Dividend ETF's Worst Year Since 2012 Was a 5.5% Loss. The Cost Showed Up in the Good Years.

AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway.

What matters in this story

Schwab's Dividend ETF's Worst Year Since 2012 Was a 5.5% Loss. The Cost Showed Up in the Good Years.

How each ticker is affected

Connected tickers

Track these names every morning.

Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.

I'd Put $500 Into Each of These 5 Dividend Stocks and Throw Away the Statement

Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?

How Much Does a 57-Year-Old Need in a Roth IRA to Collect $5,050 a Month Tax-Free for Life?

AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway.

What matters in this story

Next reads from the same story arc

Schwab's Dividend ETF's Worst Year Since 2012 Was a 5.5% Loss. The Cost Showed Up in the Good Years.

AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway.

What matters in this story

Next reads from the same story arc

Schwab's Dividend ETF's Worst Year Since 2012 Was a 5.5% Loss. The Cost Showed Up in the Good Years.

How each ticker is affected

Connected tickers

Track these names every morning.

Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.

I'd Put $500 Into Each of These 5 Dividend Stocks and Throw Away the Statement

Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?

How Much Does a 57-Year-Old Need in a Roth IRA to Collect $5,050 a Month Tax-Free for Life?